Recursion Pharmaceuticals, Inc. (RXRX)
NASDAQ: RXRX · Real-Time Price · USD
6.74
+0.10 (1.44%)
Nov 5, 2024, 3:49 PM EST - Market open
Recursion Pharmaceuticals Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Net Income | -374.93 | -328.07 | -239.48 | -186.48 | -87.01 | -61.88 |
| Depreciation & Amortization | 31.48 | 24.4 | 11.76 | 8.41 | 3.94 | 2.49 |
| Asset Writedown & Restructuring Costs | 0.13 | 1.19 | 2.81 | - | 0.87 | - |
| Stock-Based Compensation | 65.53 | 53.5 | 27.91 | 14.84 | 4.29 | 1.39 |
| Other Operating Activities | 8.73 | 11.45 | 8.56 | 4.92 | 1.66 | 0.56 |
| Change in Accounts Receivable | -6.93 | -7.76 | -0 | -5.38 | -1.12 | -0.03 |
| Change in Accounts Payable | 1.7 | -0.99 | 1.77 | 1.75 | -0.19 | -0.34 |
| Change in Unearned Revenue | -44.17 | -41.08 | 110.32 | -10 | 26.67 | - |
| Change in Other Net Operating Assets | -13.05 | -0.44 | -7.16 | 13.33 | 5.47 | 0.78 |
| Operating Cash Flow | -331.52 | -287.78 | -83.52 | -158.61 | -45.4 | -57.04 |
| Capital Expenditures | -10.65 | -11.96 | -37.06 | -39.8 | -5.83 | -3.91 |
| Cash Acquisitions | -0.07 | 1.84 | - | - | -2.6 | - |
| Sale (Purchase) of Intangibles | -3.43 | -0.6 | -0.3 | - | -0.9 | - |
| Investment in Securities | 0.48 | 0.48 | 230.61 | -231.95 | - | - |
| Other Investing Activities | - | - | - | - | 0.6 | - |
| Investing Cash Flow | -13.67 | -10.23 | 193.25 | -271.74 | -8.74 | -3.91 |
| Long-Term Debt Issued | - | - | - | - | 6.4 | 11.89 |
| Long-Term Debt Repaid | - | -0.77 | -0.09 | -12.8 | -0.08 | -11.18 |
| Net Debt Issued (Repaid) | -0.77 | -0.77 | -0.09 | -12.8 | 6.32 | 0.71 |
| Issuance of Common Stock | 412.21 | 140.9 | 154.44 | 471.34 | 0.68 | 0.07 |
| Other Financing Activities | - | - | - | - | - | -0.28 |
| Financing Cash Flow | 411.44 | 140.13 | 154.35 | 458.54 | 246.14 | 120.41 |
| Foreign Exchange Rate Adjustments | -0.33 | 0.19 | -0.31 | - | - | - |
| Net Cash Flow | 65.93 | -157.69 | 263.76 | 28.18 | 192 | 59.46 |
| Free Cash Flow | -342.16 | -299.74 | -120.58 | -198.41 | -51.23 | -60.95 |
| Free Cash Flow Margin | -689.36% | -672.43% | -302.65% | -1949.42% | -1293.03% | -2628.37% |
| Free Cash Flow Per Share | -1.50 | -1.44 | -0.69 | -1.58 | -2.35 | -2.83 |
| Cash Interest Paid | 0.1 | 0.1 | 0.06 | 0.68 | 0.99 | 0.49 |
| Levered Free Cash Flow | -226.71 | -187.37 | -105.41 | -121.93 | -34.61 | - |
| Unlevered Free Cash Flow | -226.42 | -187.31 | -105.37 | -120.09 | -33.76 | - |
| Change in Net Working Capital | 61.58 | 33.87 | -45.9 | -10.7 | -17.62 | - |
Source: S&P Capital IQ. Standard template.
Financial Sources.